Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Auteurs : Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ
Jaar : 2016
Journal : Cancer Res
Volume : 76
Pagina's : 264-74

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Auteurs : Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S
Jaar : 2016
Journal : Nat Rev Clin Oncol
Volume : 13(4)
Pagina's : 228-41

Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Jaar : 2016
Journal : Ann Oncol
Volume : 28(1)
Pagina's : 128-35

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Auteurs : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Jaar : 2016
Journal : PLoS One
Volume : 11(7)
Pagina's : e0154009

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Auteurs : Cardoso F, Vant Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, Delorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart-Gebhart M
Jaar : 2016
Journal : N Engl J Med
Volume : 375(8)
Pagina's : 717-29

Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation.

Auteurs : Hu H, Luo ML, Desmedt C, Nabavi S, Yadegarynia S, Hong A, Konstantinopoulos PA, Gabrielson E, Hines-Boykin R, Pihan G, Yuan X, Sotiriou C, Dittmer DP, Fingeroth JD, Wulf GM
Jaar : 2016
Journal : EBioMedicine
Volume : 9
Pagina's : 148-60

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Auteurs : Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart-Gebhart M, Sotiriou C, Litiere S, Pierga JY
Jaar : 2016
Journal : Eur J Cancer
Volume : 63
Pagina's : 97-104

Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance.

Auteurs : Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans ME, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R
Jaar : 2016
Journal : Clin Cancer Res
Volume : 22(21)
Pagina's : 5238-48

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Jaar : 2016
Journal : Ann Oncol
Volume : 27(8)
Pagina's : 1519-25

Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

Auteurs : Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F
Jaar : 2016
Journal : Ann Oncol
Volume : 27(8)
Pagina's : 1443-8

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.

Auteurs : Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K
Jaar : 2016
Journal : Oncoimmunology
Volume : 6
Pagina's : e1257452

MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.

Auteurs : Denis H, Van Grembergen O, Delatte B, Dedeurwaerder S, Putmans P, Calonne E, Rothé F, Sotiriou C, Fuks F, Deplus R
Jaar : 2016
Journal : Mol Biosyst
Volume : 12(2)
Pagina's : 404-13

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Auteurs : Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart-Gebhart M, Michiels S, Sotiriou C
Jaar : 2016
Journal : JAMA Oncol
Volume : 2(2)
Pagina's : 217-24

Characterization of human breast cancer tissues by infrared imaging.

Auteurs : Verdonck M, Denayer A, Delvaux B, Garaud S, de Wind R, Desmedt C, Sotiriou C, Willard-Gallo K, Goormaghtigh E
Jaar : 2016
Journal : Analyst
Volume : 141(2)
Pagina's : 606-19

Frequent incidence of BARD1 truncating mutations in germline DNA from triple negative breast cancer patients.

Auteurs : De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart-Gebhart M, Pauwels I, Teugels E
Jaar : 2016
Journal : Clin. Genet.
Volume : 89(3)
Pagina's : 336-40.

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer-Where Did It Start and Where Are We Now?

Auteurs : Gingras I, Desmedt C, Ignatiadis M, Sotiriou C
Jaar : 2015
Journal : Clin Cancer Res
Volume : 21
Pagina's : 4743-6

Genomic aberrations in young and elderly  breast cancer patients.

Auteurs : Azim HA, Nguyen B, Brohée S, Zoppoli G, Sotiriou C
Jaar : 2015
Journal : BMC Med
Volume : 13
Pagina's : 266

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart-Gebhart M, Sotiriou C
Jaar : 2015
Journal : Oncotarget
Volume : 6
Pagina's : 30306-16

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Auteurs : Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart-Gebhart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V
Jaar : 2015
Journal : Cell Rep
Volume : 13
Pagina's : 277-89

Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.

Auteurs : Gingras I, Azim HA Jr, Ignatiadis M, Sotiriou C
Jaar : 2015
Journal : Clin Adv Hematol Oncol
Volume : 13
Pagina's : 372-82